Drug intelligence / Profile preview

BDTX-4876

Development stage: Preclinical
Lead developer: Black Diamond Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

BDTX-4876 is an orally administered, highly selective small-molecule inhibitor of fibroblast growth factor receptors 2 and 3 (FGFR2/3), developed by Black Diamond Therapeutics using its Mutation-Allostery-Pharmacology (MAP) platform to target a spectrum of oncogenic “MasterKey” FGFR2/3 mutations and fusions that drive tumor growth while sparing wild-type FGFR1 and FGFR4 to improve tolerability.[1][5][7][9] It has been advanced as a development candidate for the treatment of FGFR2/3-altered solid tumors and has also been explored preclinically for skeletal dysplasia indications such as achondroplasia, but the company is currently seeking a partner for further development of this asset.[5][6][7]

Targets

FGFR3 (Fibroblast growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)

Beyond the preview

Go deeper on BDTX-4876.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BDTX-4876.

Explore the full profile